{
    "nctId": "NCT05344729",
    "briefTitle": "Clinical Trial for Effect of TQB3616 Capsule on Pharmacokinetics in Healthy Adult Subjects",
    "officialTitle": "A Randomized, Open-label, Single-center, Two-period, Two-crossover Phase I Clinical Trial to Evaluate the Effect of Food on the Pharmacokinetics of TQB3616 Capsules in Healthy Adult Subjects",
    "overallStatus": "COMPLETED",
    "conditions": "Recurrent/Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 16,
    "primaryOutcomeMeasure": "Peak concentration(Cmax)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* 1 Sign the informed consent form before the trial and fully understand the content, process and possible adverse reactions of the trial;\n* 2 Be able to complete the study according to the requirements of the study protocol;\n* 3 Subjects aged 18 to 65 years (including 18 and 65 years);\n* 4 Body mass index (BMI) \u2265 18 and \u2264 28 kg/m2, and male body weight \u2265 50 kg Female body weight \u2265 45 kg;\n* 5 Health condition: no mental disorders, no history of cardiovascular system, nervous system, respiratory system, digestive system, urinary system, endocrine system and metabolic abnormalities;\n* 6 Subjets had no plans to become pregnant and voluntarily took effective contraceptive measures from 2 weeks before dosing to at least 6 months after the last dose of study drug.\n\nExclusion Criteria:\n\n* 1 Patients with a history of neuropsychiatric, respiratory, cardiovascular, gastrointestinal, hemolymphatic, hepatic or renal insufficiency, endocrine, musculoskeletal system disease or other diseases, which may affect drug metabolism or safety as judged by the investigator;\n* 2 Allergic constitution or previous history of two or more kinds of food or drug allergy;\n* 3 Hyperactive/venous thrombotic events within 6 months, such as cerebrovascular accident (including temporary ischemic attack), deep venous thrombosis and pulmonary embolism;\n* 4 Patients with multiple factors affecting oral drugs (such as inability to swallow, gastrointestinal diseases);\n* 5 Taking any prescription drugs, over-the-counter drugs, vitamin products or herbal medicines within 1 month before taking the study drug;\n* 6 Administration of CYP3A4 inhibitors or inducers within 1 month before screening or before study drug;\n* 7 Taking special diet (including grapefruit, etc.) or strenuous exercise, or other factors affecting drug absorption, distribution, metabolism, excretion, etc. within 14 days before screening;\n* 8 Abnormal and clinically significant laboratory findings during the screening period;\n* 9 Blood donation or significant blood loss (\\> 450 mL) within 3 months prior to administration of study drug;\n* 10 Participated in any drug clinical trial within 3 months before taking the study drug;\n* 11 Smoking more than 5 cigarettes per day within 3 months before the trial;\n* 12 Positive breath alcohol test or history of alcoholism (14 units of alcohol per week: 1 unit = 360 mL of beer or 45 mL of spirits with 40% alcohol or 150 mL of wine);\n* 13 Drug screening positive or drug use 3 months before the trial;\n* 14 Inability to tolerate venipuncture for blood sampling or poor vascular status;\n* 15 Subjets cannot complete the trial due to personal reasons;\n* 16 Other conditions considered inappropriate by the investigator.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}